Literature DB >> 7471091

Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates.

D V Jackson, M C Castle, D G Poplack, R A Bender.   

Abstract

Adult rhesus monkeys were given 2-mg/sq m i.v. bolus injections of radiochemically pure tritiated vincristine (VCR). Simultaneous specimens of blood and cerebrospinal fluid (CSF) were sampled from 5 min to 72 hr following injection. CSF was obtained from Ommaya reservoirs which had been implanted s.c. in each monkey. VCR and its metabolic and/or decomposition products rapidly entered the CSF producing low concentrations in this fluid; 5 min following injection, the concentration of VCR was 2.3 nM, whereas approximately a 100-fold greater concentration (203.8 nM) was attained in the plasma. Throughout a 3-day period of observation, constant, low levels of VCR and its metabolic and/or decomposition products (2.3 to 5.7 nM) were maintained in the CSF. The principal form of VCR present in the CSF 1 hr or more after i.v. injection was a water-soluble metabolite and/or decomposition product(s). Although the levels achieved in the CSF are unlikely to be lethal to tumor cells, the finding of persistent low concentrations of VCR and its metabolic and/or decomposition products in the CSF indicates prolonged exposure of neural tissue which might result in neurotoxicity, particularly cumulative neurotoxicity following multiple doses of VCR.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7471091

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects.

Authors:  P G Bain; P L Lantos; V Djurovic; I West
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

Review 2.  Pharmacokinetic considerations in the treatment of CNS tumours.

Authors:  Susannah Motl; Yanli Zhuang; Christopher M Waters; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.

Authors:  Krzysztof Brzeziński
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

5.  Levo-corydalmine Attenuates Vincristine-Induced Neuropathic Pain in Mice by Upregulating the Nrf2/HO-1/CO Pathway to Inhibit Connexin 43 Expression.

Authors:  Lin Zhou; Luyao Ao; Yunyi Yan; Chengyuan Li; Wanting Li; Anqi Ye; Jihua Liu; Yahui Hu; Weirong Fang; Yunman Li
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.